D. E. Shaw & Co., Inc. Oric Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.41 - $9.43 $1.13 Million - $1.97 Million	-209,046 Reduced 67.99%	98,433 $905,000
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $881,908 - $1.35 Million	-145,770 Reduced 32.16%	307,479 $1.86 Million
Q2 2023 Aug 14, 2023	SELL	$4.95 - $8.4 $619,017 - $1.05 Million	-125,054 Reduced 21.62%	453,249 $3.52 Million
Q1 2023 May 15, 2023	SELL	$4.26 - $6.75 $104,301 - $165,267	-24,484 Reduced 4.06%	578,303 $3.3 Million
Q4 2022 Feb 14, 2023	BUY	$2.41 - $5.89 $166,046 - $405,815	68,899 Added 12.91%	602,787 $3.55 Million
Q3 2022 Nov 14, 2022	BUY	$3.15 - $5.24 $87,888 - $146,201	27,901 Added 5.51%	533,888 $1.71 Million
Q2 2022 Aug 15, 2022	BUY	$2.7 - $7.07 $704,937 - $1.85 Million	261,088 Added 106.61%	505,987 $2.27 Million
Q1 2022 May 16, 2022	BUY	$4.54 - $16.1 $1.11 Million - $3.94 Million	244,899 New	244,899 $1.31 Million
Q2 2021 Aug 16, 2021	SELL	$17.37 - $25.34 $170,434 - $248,636	-9,812 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$23.67 - $36.85 $232,250 - $361,572	9,812 New	9,812 $240,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.